Durian. Indonesian, Chinese and Emirati pharmaceutical companies have been working closely for future trilateral cooperation on the development of covid-19 vaccine, Indonesian Foreign Minister Retno Marsudi said on Aug.22 evening from Abu Dhabi, United Arab Emirates (UAE).
During her visit to Abu Dhabi, Minister Marsudi and State-owned Enterprises Minister Erick Thohir have attended three main meetings.
One of the meetings was between Indonesian state-owned pharmaceutical companies Kimia Farma and Indo Farma with Emirati leading artificial intelligence that actively involves in health technology Group 42 (G42). Representative from Chinese pharmaceutical giant Sinopharm also attended the meeting, Minister Marsudi explained.
G42 and Sinopharm are currently conducting their third phase of clinical examination for a covid-19 vaccine candidate.
Indonesia has sent a reviewer team to monitor the clinical trial closely, Marsudi explained further.
“In the future, there will be triangle cooperation among Indonesia-G42-Sinopharm which in principle has been agreed,” she said.
“Cooperation in the context of observing third phase of clinical test of covid-19 vaccine candidate from G42-Sinopharm works is very important for the development of vaccine in the future,” Marsudi added.
Indonesia has been conducting third phase of clinical examination of covid-19 vaccine candidate with Chinese pharmaceutical firm Sinovac.
Deals
In the meeting between Kimia Farma, Indo Farma and G42, two memorandum of understanding have been signed – vaccine product development cooperation with Kimia Farma and health cooperation in research, development, production and distribution technology based on laser and artificial intelligence for screening covid-19 virus with Indo Farma.
“Another result from our meeting with G42 was a commitment for initial provision of 10 million doses of [covid-19] vaccine in 2020,” Marsudi said. Kimia Farma will discuss further with G42 on its details.
